Stylianou et al (144), demonstrated significant shrinkage of glioblastoma tumors expressing an anti ALK scFv by tetracycline compared to tumors not expressing the antibody, providing a rationale for the clinical use of anti ALK scFv in the treatment of ALK positive tumors. The gene discussed is ALK; the disease is glioblastoma.